Tonix Pharmaceuticals Holding Corp.
TNXP
$15.52
$0.301.97%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.58% | -9.51% | -2.14% | -31.68% | -29.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.58% | -9.51% | -2.14% | -31.68% | -29.26% |
| Cost of Revenue | -12.09% | -2.82% | -43.19% | -50.02% | -34.50% |
| Gross Profit | 51.78% | -9.92% | 80.78% | -0.92% | -21.55% |
| SG&A Expenses | 233.48% | 115.97% | 8.53% | 34.08% | -11.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.85% | 47.29% | -22.45% | -19.44% | -42.82% |
| Operating Income | -112.59% | -54.13% | 24.81% | 17.74% | 44.74% |
| Income Before Tax | -125.22% | 64.11% | -12.65% | 19.08% | 49.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -125.22% | 64.11% | -12.65% | 19.08% | 49.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -125.22% | 64.11% | -12.65% | 19.08% | 49.19% |
| EBIT | -112.59% | -54.13% | 24.81% | 17.74% | 44.74% |
| EBITDA | -116.74% | -59.35% | 23.50% | 16.73% | 44.63% |
| EPS Basic | 84.18% | 99.80% | 99.47% | 99.55% | -- |
| Normalized Basic EPS | 84.18% | 99.20% | 99.54% | -- | -- |
| EPS Diluted | 84.18% | 99.80% | 99.47% | 99.55% | -- |
| Normalized Diluted EPS | 84.18% | 99.20% | 99.54% | -- | -- |
| Average Basic Shares Outstanding | 1,323.78% | 17,771.46% | 21,144.44% | -- | -- |
| Average Diluted Shares Outstanding | 1,323.78% | 17,771.46% | 21,144.44% | 18,008.00% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |